Downregulation of reelin predicts poor prognosis for glioma

Biomark Med. 2020 Jun;14(8):651-663. doi: 10.2217/bmm-2019-0609. Epub 2020 Jul 2.

Abstract

Aim: In the present study, we studied the relationship between RELN and prognosis in glioma. Materials & methods: Expression profiles and methylation data of RELN were obtained from bioinformatic datasets. Correlations between RELN and clinicopathological features and overall survival were respectively assessed using chi-square test and Kaplan-Meier analysis. Results:RELN was downregulated in glioma, and its downregulation correlated well with glioma malignancy and overall survival. Meanwhile, hypermethylation of RELN was significantly correlated with low RELN expression. Additionally, gene set enrichment analysis demonstrated that low expression of RELN correlated with many key cancer pathways, possibly highlighting the importance of RELN in carcinogenesis of brain. Conclusion:RELN may serve as a potential prognostic marker and promising target molecule for new therapy of glioma.

Keywords: bioinformatics; biomarker; glioma; malignancy; oncology; overall survival; prognosis; reelin (RELN).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / therapy
  • Cell Adhesion Molecules, Neuronal / genetics*
  • DNA Methylation
  • Down-Regulation*
  • Extracellular Matrix Proteins / genetics*
  • Female
  • Gene Expression Profiling / methods*
  • Gene Expression Regulation, Neoplastic*
  • Glioma / diagnosis
  • Glioma / genetics*
  • Glioma / therapy
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Nerve Tissue Proteins / genetics*
  • Prognosis
  • Reelin Protein
  • Serine Endopeptidases / genetics*

Substances

  • Cell Adhesion Molecules, Neuronal
  • Extracellular Matrix Proteins
  • Nerve Tissue Proteins
  • Reelin Protein
  • RELN protein, human
  • Serine Endopeptidases